Role of LL-37 in thrombotic complications in patients with COVID-19
-
Published:2022-05-21
Issue:6
Volume:79
Page:
-
ISSN:1420-682X
-
Container-title:Cellular and Molecular Life Sciences
-
language:en
-
Short-container-title:Cell. Mol. Life Sci.
Author:
Duan Zilei, Zhang Juan, Chen Xue, Liu Ming, Zhao Hongwen, Jin Lin, Zhang Zhiye, Luan Ning, Meng Ping, Wang Jing, Tan Zhaoxia, Li Yaxiong, Deng Guohong, Lai RenORCID
Abstract
AbstractBlood clot formation induced by dysfunctional coagulation is a frequent complication of coronavirus disease 2019 (COVID-19) and a high-risk factor for severe illness and death. Neutrophil extracellular traps (NETs) are implicated in COVID-19-induced immunothrombosis. Furthermore, human cathelicidin, a NET component, can perturb the interaction between the SARS-CoV-2 spike protein and its ACE2 receptor, which mediates viral entry into cells. At present, however, the levels of cathelicidin antimicrobial peptides after SARS-CoV-2 infection and their role in COVID-19 thrombosis formation remain unclear. In the current study, we analyzed coagulation function and found a decrease in thrombin time but an increase in fibrinogen level, prothrombin time, and activated partial thromboplastin time in COVID-19 patients. In addition, the cathelicidin antimicrobial peptide LL-37 was upregulated by the spike protein and significantly elevated in the plasma of patients. Furthermore, LL-37 levels were negatively correlated with thrombin time but positively correlated with fibrinogen level. In addition to platelet activation, cathelicidin peptides enhanced the activity of coagulation factors, such as factor Xa (FXa) and thrombin, which may induce hypercoagulation in diseases with high cathelicidin peptide levels. Injection of cathelicidin peptides promoted the formation of thrombosis, whereas deletion of cathelicidin inhibited thrombosis in vivo. These results suggest that cathelicidin antimicrobial peptide LL-37 is elevated during SARS-CoV-2 infection, which may induce hypercoagulation in COVID-19 patients by activating coagulation factors.
Funder
Chinese Academy of Sciences National Natural Science Foundation of China Yunnan Provincial Science and Technology Department PLA Youth Talent Project Chongqing Science and Technology Commission Yunnan Provincial Postdoctoral Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Cellular and Molecular Neuroscience,Pharmacology,Molecular Biology,Molecular Medicine
Reference64 articles.
1. Ortiz-Muñoz G, Yu MA, Lefrançais E, Mallavia B, Valet C, Tian JJ, Ranucci S, Wang KM, Liu Z, Kwaan N, Dawson D, Kleinhenz ME, Khasawneh FT, Haggie PM, Verkman AS, Looney MR (2020) Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation. J Clin Investig 130:2041–2053 2. Akel T, Qaqa F, Abuarqoub A, Shamoon F (2020) Pulmonary embolism: a complication of COVID 19 infection. Thromb Res 193:79–82 3. Tamburello A, Bruno G, Marando M (2020) COVID-19 and pulmonary embolism: not a coincidence. Eur J Case Rep Intern Med 7:001692 4. Carbone F, Montecucco F, Twickler T (2020) SARS-CoV-2: what is known and what there is to know–focus on coagulation and lipids. European J Clin Invest 50:e13311 5. Poor HD, Ventetuolo CE, Tolbert T, Chun G, Serrao G, Zeidman A, Dangayach NS, Olin J, Kohli-Seth R, Powell CA (2020) COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med 10:e44
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|